The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer
Open accessAbstract
Ovarian cancer (OvCa) is the fifth most common cause of death from all cancers among women in United Sates and the leading cause of death from gynecological malignancies. While most OvCa patients initially respond to surgical debulking and chemotherapy, 75% of patients later succumb to the disease. Thus, there is an urgent need to test novel therapeutic agents to counteract the high mortality rate associated with OvCa. In this context, we have developed and engineered Nanoceria (NCe), nanoparticles of cerium oxide, possessing anti-oxidant properties, to be used as a therapeutic agent in OvCa. We show for the first time that NCe significantly inhibited production of reactive oxygen species (ROS) in A2780 cells, attenuated growth factor (SDF1, HB-EGF, VEGF(165) and HGF) mediated cell migration and invasion of SKOV3 cells, without affecting the cell proliferation. NCe treatment also inhibited VEGF(165) induced proliferation, capillary tube formation, activation of VEGFR2 and MMP2 in human umbilical vascular endothelial cells (HUVEC). NCe (0.1 mg/kg body weigh) treatment of A2780 ovarian cancer cells injected intra-peritoneally in nude mice showed significant reduction (p<0.002) in tumor growth accompanied by decreased tumor cell proliferation as evident from reduced tumor size and Ki67 staining. Accumulation of NCe was found in tumors isolated from treated group using transmission electron microscopy (TEM) and inductively coupled plasma mass spectroscopy (ICP-MS). Reduction of the tumor mass was accompanied by attenuation of angiogenesis, as observed by reduced CD31 staining and specific apoptosis of vascular endothelial cells. Collectively, these results indicate that cerium oxide based NCe is a novel nanoparticle that can potentially be used as an anti-angiogenic therapeutic agent in ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · cited 1×
“This abnormal angiogenesis is required for the growth, survival, and metastasis of most solid tumors [7,8].”
BackgroundTumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
Weidner, N., Carroll, P. R., Flax, J. D., Blumenfeld, W., & Folkman, J. (1993) · PubMed Central · Cited by 1,620
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Size dependency variation in lattice parameter and valency states in nanocrystalline cerium oxide
Deshpande, S., Patil, S., Kuchibhatla, S. V., & Seal, S. (2005) · Applied Physics Letters · doi:10.1063/1.2061873 · Cited by 1,135
Self-citationProtein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential
Patil, S., Sandberg, A., Heckert, E., Self, W., & Seal, S. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.07.029 · Cited by 1,044
Self-citationBurger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides
Chen, J., Patil, S., Seal, S., & McGinnis, J. F. (2006) · Nature Nanotechnology · doi:10.1038/nnano.2006.91 · Cited by 880
Self-citationVacancy Engineered Ceria Nanostructures for Protection from Radiation-Induced Cellular Damage
Tarnuzzer, R. W., Colon, J., Patil, S., & Seal, S. (2005) · Nano Letters · doi:10.1021/nl052024f · Cited by 816
Self-citationRelation of neovascularisation to metastasis of non-small-cell lung cancer
Macchiarini, P., Fontanini, G., Squartini, F., Angeletti, C. A., & Hardin, M. J. (1992) · The Lancet · doi:10.1016/0140-6736(92)93217-b · Cited by 764
Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons
Das, M., Patil, S., Bhargava, N., Kang, J.-F., Riedel, L. M., Seal, S., & Hickman, J. J. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.036 · Cited by 760
Self-citationCannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Takahashi, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2768 · Cited by 749
Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy
Ushio-Fukai, M., & Nakamura, Y. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.044 · Cited by 651
Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Xia, C., Meng, Q., Liu, L.-Z., Rojanasakul, Y., Wang, X.-R., & Jiang, B.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0783 · Cited by 507
VEGF Receptor Signal Transduction
Matsumoto, T., & Claesson-Welsh, L. (2001) · Science's STKE · doi:10.1126/stke.2001.112.re21 · Cited by 502
Kroll, J., & Waltenberger, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32521 · Cited by 430
Role of Vascular Endothelial Growth Factor in Ovarian Cancer
Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65669-6 · Cited by 392
Nanoceria as antioxidant: Synthesis and biomedical applications
Karakoti, A. S., Monteiro-Riviere, N. A., Aggarwal, R., Davis, J. P., Narayan, R. J., Self, W. T., McGinnis, J., & Seal, S. (2008) · JOM · doi:10.1007/s11837-008-0029-8 · Cited by 385
Self-citationColon, J., Hsieh, N., Ferguson, A., Kupelian, P., Seal, S., Jenkins, D. W., & Baker, C. H. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.01.010 · Cited by 381
Self-citationVascular endothelial growth factor expression in early stage ovarian carcinoma
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., & Ramakrishnan, S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a · Cited by 364
Vascular endothelial growth factor
Ferrara, N. (1996) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00387-5 · Cited by 355
PEGylated Nanoceria as Radical Scavenger with Tunable Redox Chemistry
Karakoti, A. S., Singh, S., Kumar, A., Malinska, M., Kuchibhatla, S. V. N. T., Wozniak, K., Self, W. T., & Seal, S. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9051087 · Cited by 343
Self-citationRattan, R., Giri, S., Singh, A. K., & Singh, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507443200 · Cited by 339
Self-citationRattan, R., Graham, R. P., Maguire, J. L., Giri, S., & Shridhar, V. (2011) · Neoplasia · doi:10.1593/neo.11148 · Cited by 316
Self-citationBio‐distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice
Hirst, S. M., Karakoti, A., Singh, S., Self, W., Tyler, R., Seal, S., & Reilly, C. M. (2013) · Environmental Toxicology · doi:10.1002/tox.20704 · Cited by 300
Self-citationProtection from radiation-induced pneumonitis using cerium oxide nanoparticles
Colon, J., Herrera, L., Smith, J., Patil, S., Komanski, C., Kupelian, P., Seal, S., Jenkins, D. W., & Baker, C. H. (2009) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2008.10.003 · Cited by 295
Self-citationThymosin β4 Accelerates Wound Healing
Malinda, K. M., Kleinman, H. K., Sidhu, G. S., Mani, H., Banaudha, K., Maheshwari, R. K., & Goldstein, A. L. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00708.x · Cited by 274
Bharali, D. J., & Mousa, S. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.007 · Cited by 251
Alili, L., Sack, M., Karakoti, A. S., Teuber, S., Puschmann, K., Hirst, S. M., Reilly, C. M., Zanger, K., Stahl, W., Das, S., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.056 · Cited by 249
Self-citationMetformin attenuates ovarian cancer cell growth in an AMP‐kinase dispensable manner
Rattan, R., Giri, S., Hartmann, L. C., & Shridhar, V. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00954.x · Cited by 223
Self-citationChan, D. W., Liu, V. W. S., Tsao, G. S. W., Yao, K.-M., Furukawa, T., Chan, K. K. L., & Ngan, H. Y. S. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn167 · Cited by 215
Liu, L.-Z., Hu, X.-W., Xia, C., He, J., Zhou, Q., Shi, X., Fang, J., & Jiang, B.-H. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.08.003 · Cited by 205
Prognostic factors in ovarian cancer.
Friedlander, M. L., & Dembo, A. J. (1991) · PubMed · Cited by 196
From Nanotechnology to Nanomedicine: Applications to Cancer Research
Seigneuric, R., Markey, L., S.A. Nuyten, D., Dubernet, C., T.A. Evelo, C., Finot, E., & Garrido, C. (2010) · Current Molecular Medicine · doi:10.2174/156652410792630634 · Cited by 182
Overview of anti-angiogenic agents in development for ovarian cancer
Burger, R. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.035 · Cited by 150
Early Detection of Ovarian Cancer: Promise and Reality
Bast, R. C., Urban, N. D., Shridhar, V., Smith, D., Zhang, Z., Skates, S. J., Lu, K. H., Liu, J., Fishman, D. A., & Mills, G. B. (2002) · Cancer treatment and research · doi:10.1007/978-1-4757-3587-1_3 · Cited by 143
Self-citationBevacizumab toxicities and their management in ovarian cancer
Randall, L. M., & Monk, B. J. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.021 · Cited by 128
Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death
Giri, S., Khan, M., Rattan, R., Singh, I., & Singh, A. K. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600084-jlr200 · Cited by 115
Self-citationAmin, K. A., Hashem, K. S., & Amin, K. A. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s15308 · Cited by 111
Hardas, S. S., Butterfield, D. A., Rukhsana Sultana, A., Tseng, M. T., Dan, M., Florence, R. L., Unrine, J. M., Graham, U. M., Wu, P., Grulke, E. A., et al. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq137 · Cited by 111
Interleukin 8: An Autocrine Growth Factor for Human Ovarian Cancer
Xu, L., & Fidler, I. J. (2001) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504001108747567 · Cited by 107
Penson, R. T., Dizon, D. S., Cannistra, S. A., Roche, M. R., Krasner, C. N., Berlin, S. T., Horowitz, N. S., DiSilvestro, P., Matulonis, U. A., Lee, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7900 · Cited by 105
Prognostic factors in ovarian cancer
Trope, C. G. (1998) · Cancer treatment and research · doi:10.1007/978-1-4615-5447-9_11 · Cited by 91
Giri, S., Khan, M., Nath, N., Singh, I., & Singh, A. K. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05279.x · Cited by 77
Self-citationAngiogenesis and ovarian cancer
Gómez-Raposo, C., Mendiola, M., Barriuso, J., Casado, E., Hardisson, D., & Redondo, A. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0406-y · Cited by 70
Antiangiogenic drugs in ovarian cancer
Markman, M. M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903120907 · Cited by 13
Cited by
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
Wu, J., Wang, X., Wang, Q., Lou, Z., Li, S., Zhu, Y., Qin, L., & Wei, H. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00457a · Cited by 4,108
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes
Wei, H., & Wang, E. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35486e · Cited by 3,779
Butyrate: A Double-Edged Sword for Health?
Liu, H., Wang, J., He, T., Becker, S., Zhang, G., Li, D., & Ma, X. (2018) · Advances in Nutrition · doi:10.1093/advances/nmx009 · Cited by 1,144
Lanthanide Nanoparticles: From Design toward Bioimaging and Therapy
Dong, H., Du, S.-R., Zheng, X.-Y., Lyu, G.-M., Sun, L.-D., Li, L.-D., Zhang, P.-Z., Zhang, C., & Yan, C.-H. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00091 · Cited by 1,126
Recent Advances in Nanozyme Research
Wang, H., Wan, K., & Shi, X. (2019) · Advanced Materials · doi:10.1002/adma.201805368 · Cited by 974
Metadata
- Authors
- Giri, S., Karakoti, A., Graham, R. P., Maguire, J. L., Reilly, C. M., Seal, S., Rattan, R., & Shridhar, V.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-31
- Volume
- 8
- Issue
- 1
- Pages
- e54578
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2034564620
- Cited by
- 273
- References
- 49
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.